{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:56:35Z","timestamp":1795107395078,"version":"4.10.3"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>The literature was searched for publications on TXA in the treatment of melasma using MEDLINE, Scopus, and Google Scholar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8\u201312 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Oral TXA is a safe and efficacious treatment for refractory melasma. It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000001518","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T19:19:17Z","timestamp":1524251957000},"page":"814-825","source":"Crossref","is-referenced-by-count":113,"title":["Oral Tranexamic Acid for the Treatment of Melasma: A Review"],"prefix":"10.1097","volume":"44","author":[{"given":"Harini R.","family":"Bala","sequence":"first","affiliation":[{"name":"Skin and Cancer Foundation Inc., Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senhong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Monash Health, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine","family":"Wong","sequence":"additional","affiliation":[{"name":"Skin and Cancer Foundation Inc., Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit.G.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas, Southwestern Medical Center, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Skin and Cancer Foundation Inc., Melbourne, Australia;"},{"name":"Department of Dermatology, The Royal Children's Hospital, Victoria, Australia;"},{"name":"Department of Dermatology, St Vincent's Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ajd.12290","article-title":"Melasma: clinical diagnosis and management options","volume":"56","author":"Rodrigues","year":"2015","journal-title":"Australas J Dermatol"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaad.2011.06.001","article-title":"Melasma: a comprehensive update: part II","volume":"65","author":"Sheth","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2010.12.046","article-title":"Melasma: a comprehensive update: part I","volume":"65","author":"Sheth","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdv.12049","article-title":"Melasma pathogenesis and influencing factors\u2014an overview of the latest research","volume":"27","author":"Passeron","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/jid.2010.95","article-title":"Impact of long-wavelength UVA and visible light on melanocompetent skin","volume":"130","author":"Mahmoud","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R6-20230814","first-page":"1469","article-title":"Protection afforded by sunscreens containing inorganic sunscreening agents against blue light sensitivity induced by aminolevulinic acid","volume":"34","author":"Bissonnette","year":"2008","journal-title":"Dermatol Surg"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: a clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2007.01.009","article-title":"The vascular characteristics of melasma","volume":"46","author":"Kim","year":"2007","journal-title":"J Dermatol Sci"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.0007-0963.2001.04556.x","article-title":"Melasma: histopathological characteristics in 56 Korean patients","volume":"146","author":"Kang","year":"2002","journal-title":"Br J Dermatol"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/1346-8138.12573","article-title":"Inflammatory features of melasma lesions in Asian skin","volume":"41","author":"Noh","year":"2014","journal-title":"J Dermatol"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546630050517333","article-title":"A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma","volume":"11","author":"Ennes","year":"2000","journal-title":"J Dermatol Treat"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5021\/ad.2015.27.3.250","article-title":"Tranexamic acid diminishes laser-induced melanogenesis","volume":"27","author":"Kim","year":"2015","journal-title":"Ann Dermatol"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5694\/mja13.00023","article-title":"Tranexamic acid and trauma","volume":"200","author":"Gruen","year":"2014","journal-title":"Med J Aust"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/dth.12200","article-title":"The efficacy of tranexamic acid in the treatment of melasma","volume":"28","author":"Bagherani","year":"2015","journal-title":"Dermatol Ther"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/WHE.11.55","article-title":"Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study","volume":"7","author":"Lukes","year":"2011","journal-title":"Women's health"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/phpp.12231","article-title":"The gender differences in the inhibitory action of UVB-induced melanocyte activation by the administration of tranexamic acid","volume":"32","author":"Hiramoto","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","article-title":"Treatment of melasma with oral administration of tranexamic acid","volume":"36","author":"Wu","year":"2012","journal-title":"Aesthet Plast Surg"},{"key":"R18-20230814","first-page":"3129","article-title":"Treatment of melasma with tranexamic acid","volume":"13","author":"Sadako","year":"1979","journal-title":"Clin Rep"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jocd.12026","article-title":"Tranexamic acid: an important adjuvant in the treatment of melasma","volume":"12","author":"Tse","year":"2013","journal-title":"J Cosmet Dermatol"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1248\/jhs.53.389","article-title":"Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium","volume":"53","author":"Maeda","year":"2007","journal-title":"J Health Sci"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1011-1344(98)00212-7","article-title":"Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation","volume":"47","author":"Maeda","year":"1998","journal-title":"J Photochem Photobiol B"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1684\/ejd.2010.0912","article-title":"Tranexamic acid can treat ultraviolet radiation-induced pigmentation in Guinea pigs","volume":"20","author":"Li","year":"2010","journal-title":"Eur J Dermatol"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/ajd.12474","article-title":"Oral tranexamic acid lightens refractory melasma","volume":"58","author":"Tan","year":"2017","journal-title":"Australas J Dermatol"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/01.ATV.17.3.454","article-title":"Basic fibroblast growth factor\u2013induced angiogenic phenotype in mouse endothelium a study of aortic and microvascular endothelial cell lines","volume":"17","author":"Bastaki","year":"1997","journal-title":"Arteriosclerosis Thromb Vasc Biol"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"e17229","DOI":"10.1371\/journal.pone.0017229","article-title":"Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature","volume":"6","author":"Reichel","year":"2011","journal-title":"PLoS One"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4103\/0019-5154.164416","article-title":"Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial","volume":"60","author":"Padhi","year":"2015","journal-title":"Indian J Dermatol"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/09546634.2011.643220","article-title":"Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser","volume":"24","author":"Cho","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0923-1811(92)90050-L","article-title":"Determination of the action spectrum for UV-induced plasminogen activator synthesis in mouse keratinocytes in vitro","volume":"4","author":"Takashima","year":"1992","journal-title":"J Dermatol Sci"},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/phpp.12131","article-title":"Tranexamic acid suppresses ultraviolet B eye irradiation-induced melanocyte activation by decreasing the levels of prohormone convertase 2 and alpha-melanocyte-stimulating hormone","volume":"30","author":"Hiramoto","year":"2014","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/1523-1747.ep12471536","article-title":"Stimulatory effect of prostaglandin E 2 on the configuration of normal human melanocytes in vitro","volume":"89","author":"Tomita","year":"1987","journal-title":"J Invest Dermatol"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-0749.1992.tb00562.x","article-title":"Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation","volume":"5","author":"Tomita","year":"1992","journal-title":"Pigment Cel Res"},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"191S","DOI":"10.1038\/jid.1993.75","article-title":"Influence of inflammatory mediators and cytokines on human melanocyte function","volume":"100","author":"Morelli","year":"1993","journal-title":"J Invest Dermatol"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/1523-1747.ep12365904","article-title":"Analysis of the mechanism of ultraviolet (UV) B radiation\u2013induced prostaglandin E 2 synthesis by human epidermoid carcinoma cells","volume":"101","author":"Grewe","year":"1993","journal-title":"J Invest Dermatol"},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/bmj.4.5729.214","article-title":"Treatment of menorrhagia with tranexamic acid. A double-blind trial","volume":"4","author":"Callender","year":"1970","journal-title":"Br Med J"},{"key":"R35-20230814","first-page":"413","article-title":"Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety","volume":"4","author":"Leminen","year":"2012","journal-title":"Int J Womens Health"},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2003.11.067","article-title":"Linear hyperpigmentation with extensive epidermal apoptosis: a variant of linear lichen planus pigmentosus?","volume":"50","author":"Akagi","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1755-3768.1981.tb02985.x","article-title":"Ophthalmological examination of patients in long-term treatment with tranexamic acid","volume":"59","author":"Theil","year":"1981","journal-title":"Acta ophthalmologica"},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-199957060-00017","article-title":"Tranexamic acid: a review of its use in surgery and other indications","volume":"57","author":"Dunn","year":"1999","journal-title":"Drugs"},{"key":"R39-20230814","first-page":"667","article-title":"Efficacy and safety of tranexamic acid in control of bleeding following TKR: a randomized clinical trial","volume":"53","author":"Kakar","year":"2009","journal-title":"Indian J Anaesth"},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1302\/0301-620X.78B3.0780434","article-title":"Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients","volume":"78","author":"Benoni","year":"1996","journal-title":"J Bone Joint Surg Br"},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/00016349009036161","article-title":"Treatment with the fibrinolytic inhibitor tranexamic acid\u2013risk for thrombosis?","volume":"69","author":"Bekassy","year":"1990","journal-title":"Acta Obstetricia Gynecologica Scand"},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2217\/WHE.11.65","article-title":"Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid","volume":"7","author":"Muse","year":"2011","journal-title":"Womens Health (Lond)"},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1600-0609.2002.01607.x","article-title":"Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia","volume":"68","author":"Taparia","year":"2002","journal-title":"Eur J Haematol"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000205692","article-title":"Multiple pulmonary emboli in a patient with afibrinogenaemia","volume":"79","author":"Cronin","year":"1988","journal-title":"Acta Haematologica"},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1076029609340902","article-title":"Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid","volume":"17","author":"Krivokuca","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0196-0644(89)80352-X","article-title":"After antifibrinolytic therapy","volume":"18","author":"Woo","year":"1989","journal-title":"Ann Emerg Med"},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4172\/2329-6887.1000171","article-title":"Systematic review of tranexamic acid adverse reactions","volume":"3","author":"Calapai","year":"2015","journal-title":"J Pharmacovigilance"},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0037-1616122","article-title":"No increased risk of venous thrombosis in women taking tranexamic acid","volume":"86","author":"Berntorp","year":"2001","journal-title":"Thromb Haemost"},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"g4829","DOI":"10.1136\/bmj.g4829","article-title":"Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety","volume":"349","author":"Poeran","year":"2014","journal-title":"BMJ"},{"key":"R50-20230814","first-page":"CD001886","article-title":"Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion","volume":"19","author":"Henry","year":"2011","journal-title":"Cochrane Libr"},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-0528.2008.01926.x","article-title":"The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the general practice research database","volume":"116","author":"Sundstrom","year":"2009","journal-title":"BJOG"},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis","volume":"75","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"23 Suppl 1","key":"R53-20230814","first-page":"I9","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/jdv.12209","article-title":"Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial","volume":"28","author":"Li","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R55-20230814","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/dsu.12060","article-title":"Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial","volume":"39","author":"Shin","year":"2013","journal-title":"Dermatol Surg"},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2336\/nishinihonhifu.47.1101","article-title":"Oral administration therapy with tranexamic acid for melasma","volume":"47","author":"Hajime","year":"1985","journal-title":"Nishinihon J Dermatol"},{"key":"R57-20230814","first-page":"676","article-title":"Treatment of melasma with oral tranexamic acid","volume":"30","author":"Higashi","year":"1988","journal-title":"Skin Res"},{"key":"R58-20230814","first-page":"178","article-title":"The clinical study of acidum tranexamicum on melasma","volume":"3","author":"Zhu","year":"2001","journal-title":"Pharm Prog"},{"key":"R59-20230814","first-page":"361","article-title":"Effectiveness of tranexamic acid in treating melasma and observation of its safety (Chinese)","volume":"11","author":"Liu","year":"2005","journal-title":"Chin J Med Aesth Cosmet"},{"key":"R60-20230814","first-page":"010","article-title":"Treatment of melasma with oral administration of tranexamic acid [J]","volume":"2","author":"Wu","year":"2008","journal-title":"Chin J Aesthet Plast Surg"},{"key":"R61-20230814","first-page":"437","article-title":"Tranexamic acid and melasma","volume":"44","author":"Mafune","year":"2008","journal-title":"Farumashia"},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3126\/kumj.v10i4.10993","article-title":"Oral tranexamic acid for the treatment of melasma","volume":"10","author":"Karn","year":"2014","journal-title":"Kathmandu Univ Med J"},{"key":"R63-20230814","first-page":"198","article-title":"Oral tranexamic acid in treatment of melasma in Pakistani population: a pilot study","volume":"24","author":"Aamir","year":"2014","journal-title":"J Pakistan Assoc Dermatologists"},{"key":"R64-20230814","doi-asserted-by":"crossref","first-page":"e12465","DOI":"10.1111\/dth.12465","article-title":"Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies","volume":"30","author":"Taraz","year":"2016","journal-title":"Dermatol Ther"},{"key":"R65-20230814","first-page":"174","article-title":"Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma","volume":"1","author":"Steiner","year":"2009","journal-title":"Surg Cosmet Dermatol"},{"key":"R66-20230814","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-2668","article-title":"Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review","author":"Kim","year":"2017","journal-title":"Acta Dermato Venereologica"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201806000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T15:26:45Z","timestamp":1692026805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201806000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001518","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}